BRKR Stock Recent News

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced the launch of the Beacon Discovery™ Optofluidic System at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025. This new Beacon benchtop system offers an accessible entry point into live single-cell functional analysis. Building on Bruker's proprietary Opto-Electrical Positioning (OEP) technology and scalable OptoSelect™ microfluidic chips, Beacon Discovery complements the floor-st.

Solis Agrosciences, the trusted partner for high-quality AgTech research services, announced that it has hired Crystal Winkeler as Chief Business Officer.

SAN JOSE, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced the launch of the nVista 2P miniature, two-photon microscope, a groundbreaking addition to the Inscopix product line for functional imaging of freely behaving animals. It leverages advanced two-photon fluorescence microscopy technology to enable high-resolution imaging at greater depths with 3D data reconstruction, providing researchers with unprecedented insights into neuronal activity. Featuring several innov.

MUNICH--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (NASDAQ: BRKR) today announced a majority investment in RECIPE Chemicals + Instruments GmbH, based in Munich, Germany. RECIPE is a leading European provider of vendor-agnostic therapeutic drug monitoring (TDM) and other clinical in vitro diagnostic kits for LC-MS/MS, HPLC, and ICP-MS assays. Financial details of the transaction were not disclosed. RECIPE has over 60 employees and continues to operate under the leadership of Managing Director Dr. Gerno.

BRKR announces a new partnership with NGS bioinformatics solution provider Ridom GmbH.

BRKR's latest innovation offers 1H NMR and a choice of 15 X-nuclei with just one click.

Bruker Corporation BRKR reported preliminary revenue Friday for the first quarter that ended March 31, 2025, of $795 million to $800 million compared to a consensus of $758.85 million.

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced preliminary revenue for the first quarter ended March 31, 2025, in a range of $795 million to $800 million, comparing favorably to the Company's earlier outlook and well ahead of consensus. This estimated range implies reported revenue growth of approximately 10% year-over-year, with low-double digit percentage constant exchange rate revenue growth. Bruker estimates non-GAAP organic revenue growth in the first.

VIENNA--(BUSINESS WIRE)---- $BRKR #BRKR--At the ESCMID Global 2025 conference, Bruker´s Microbiology and Infection Diagnostics division is announcing the expansion of its microbiology solutions into Next-Generation Sequencing (NGS) applications, with new, research-use only NGS-based solutions in epidemiology and hospital acquired infection (HAI) tracing. Bruker has entered into a strategic collaboration for NGS bioinformatics applications in microbiology and infectious disease testing with Ridom GmbH, based in.